forum
DIVISLAB Share Price Target
Divi's Laboratories Ltd.
Sector: Pharmaceuticals and health care
Sector: Pharmaceuticals and health care
DIVISLAB Share Price *
1,642 +13.65 (0.84%)
* (quote may be delayed)
DIVISLAB Share Price Forecast - Consensus
| No. of reports in last year | 6 |
| No. of analysts | 4 |
| Average Consensus Forecast | 1732.33 |
| Consensus Potential | 5.82% |
DIVISLAB Share Price Target - Broker Reports - 2019
Sharekhan
19-Aug-19
Price @ Call: 1500.15
Target: 1800
BUY
Maintain Buy with marginally lower PT of Rs. 1,800:
The stock is down by 13-14% from its high and is trading at 21.6x its FY2021E earnings. Although Q1FY2020 performance was below our estimates, we feel long-term growth is likely to remain healthy, led by aggressive capacity expansion plans to monetise opportunities in the U.S. and China. However, taking into account lowered OPM guidance, we have reduced our earnings estimates by 5%/6% for FY2020E and FY2021E,respectively. We expect the company to report sales and profit CAGRs of21% and 18%, respectively, during FY2019-FY2021E. We maintain our Buy rating on the stock with marginally lower PT of Rs. 1,800.
The stock is down by 13-14% from its high and is trading at 21.6x its FY2021E earnings. Although Q1FY2020 performance was below our estimates, we feel long-term growth is likely to remain healthy, led by aggressive capacity expansion plans to monetise opportunities in the U.S. and China. However, taking into account lowered OPM guidance, we have reduced our earnings estimates by 5%/6% for FY2020E and FY2021E,respectively. We expect the company to report sales and profit CAGRs of21% and 18%, respectively, during FY2019-FY2021E. We maintain our Buy rating on the stock with marginally lower PT of Rs. 1,800.
Karvy Stock Broking
12-Aug-19
Price @ Call: 1666.75
Target: 1744
HOLD
Lower margins, limited upside
We downgrade our revenue estimates for FY20E/FY21E by 2.9%/3% due to downgrade in Customs Synthesis and Generics business. We downgrade our EBITDA margins by 190 bps/130 bps to Rs 36.2/ Rs 36.7 for FY20E/FY21E. We downgrade our EPS estimates for FY20E/FY21E by 5.1%/4.2% to Rs54/ Rs64.3 respectively. We downgrade our price target to Rs 1744 based on 27x FY21E and maintain our HOLD rating.
We downgrade our revenue estimates for FY20E/FY21E by 2.9%/3% due to downgrade in Customs Synthesis and Generics business. We downgrade our EBITDA margins by 190 bps/130 bps to Rs 36.2/ Rs 36.7 for FY20E/FY21E. We downgrade our EPS estimates for FY20E/FY21E by 5.1%/4.2% to Rs54/ Rs64.3 respectively. We downgrade our price target to Rs 1744 based on 27x FY21E and maintain our HOLD rating.
ICICIdirect.com
28-May-19
Price @ Call: 1593.35
Target: 1780
HOLD
As per the management, Q4 margins were just a kind of aberration. The management continues to expect normalised margins, going forward. On the capex front, to further augment capacities besides preparing for growing opportunities arising due to China factor, the company has earmarked an aggressive capex of ~Rs 1700 crore, over and above ~ Rs 2000 crore spent in the last five years. Margins are also likely to get support from extensive backward integration, product mix and operating leverage. We ascribe a target price of Rs 1780 based on 26x FY21E EPS of Rs 68.4.
ICICIdirect.com
4-Feb-19
Price @ Call: 1592.98
Target: 1800
BUY
DIVISLAB Share Price Target - Broker Reports - 2018
Axis Direct
5-Dec-18
Price @ Call: 1481.21
Target: 1600
BUY
Sharekhan
17-Sep-18
Price @ Call: 1305
Target: 1670
BUY
Sharekhan
7-Aug-18
Price @ Call: 1194.2
Target: 1455
BUY
Motilal Oswal
6-Aug-18
Price @ Call: 1210
Target: 1270
NEUTRAL
ICICIdirect.com
6-Aug-18
Price @ Call: 1210
Target: 1380
BUY
Edelweiss
29-May-18
Price @ Call: 1092
Target: 1020
BOOK PROFIT
Motilal Oswal
28-May-18
Price @ Call: 1114.84
Target: 1200
NEUTRAL
Sharekhan
15-Mar-18
Price @ Call: 1059
Target: 1275
BUY
Edelweiss
29-Jan-18
Price @ Call: 1095.91
Target: 1020
REDUCE
DIVISLAB Share Price Target - Broker Reports - 2017
Sharekhan
13-Nov-17
Price @ Call: 997.21
Target: 1275
BUY
ICICIdirect.com
7-Nov-17
Price @ Call: 1049.5
Target: 1090
HOLD
Edelweiss
3-Nov-17
Price @ Call: 1049.14
Target: 920
REDUCE
Motilal Oswal
2-Nov-17
Price @ Call: 1079.56
Target: 1100
NEUTRAL
HDFC Securities
16-Oct-17
Price @ Call: 873.19
Target: 1070
BUY
Axis Direct
6-Oct-17
Price @ Call: 863.5
Target: 1080
BUY
Sharekhan
26-Sep-17
Price @ Call: 952.1
Target: 1040
HOLD
Axis Direct
21-Sep-17
Price @ Call: 942.75
Target: 1600
BUY
Edelweiss
6-Sep-17
Price @ Call: 723.65
Target: 545
REDUCE
Motilal Oswal
6-Feb-17
Price @ Call: 761
Target: 815
NEUTRAL
Edelweiss
3-Feb-17
Price @ Call: 760
Target: 1000
BUY
Religare
3-Feb-17
Price @ Call: 760.35
Target: 1120
BUY
DIVISLAB Share Price Target - Broker Reports - 2016
Religare
7-Dec-16
Price @ Call: 1163.6
Target: 1400
BUY
ICICIdirect.com
17-Nov-16
Price @ Call: 1156
Target: 1305
BUY
Religare
15-Nov-16
Price @ Call: 1165.9
Target: 1400
BUY
Edelweiss
11-Nov-16
Price @ Call: 1221
Target: 1320
BUY
ICICIdirect.com
1-Jun-16
Price @ Call: 1100
Target: 1260
BUY